2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01259050 (ClinicalTrials.gov) | October 2010 | 10/12/2010 | Safety Study of High Doses of Zinc in ALS Patients | Phase 1 Open Label Study of Zinc Therapy in ALS Patients | Amyotrophic Lateral Sclerosis | Drug: Zinc and Copper | Phoenix Neurological Associates, LTD | NULL | Completed | 18 Years | 85 Years | Both | 10 | Phase 1/Phase 2 | United States |